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Abstract
Background: It is generally accepted that dialysis may lower plasma osmolality at a faster rate than changes in
ocular osmolality. This osmotic difference causes water to migrate from the plasma into the aqueous humor,
increasing intraocular pressure. Certain authors have described IOP increase in patients with narrow angles.
Case presentation: Here we report a neovascular glaucoma patient who experienced a substantial increase in IOP
associated with severe eye pain and blurred vision during sessions of dialysis. The patient had been refractory to
several antiglaucoma drugs and improved after intravenous administration of 20 % hyperosmotic glucose solution
with dialysis and pan-retinal photocoagulation.
Conclusion: It is the first report in which intravenous glucose administration and reduction of neovascularization
by argon laser pan-retinal photocoagulation successfully managed IOP increase during dialysis in neovascular
glaucoma. Further clinical studies are required to confirm our results.
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Background
Eye complications may occur during or after hemodialysis
in patients with end stage renal disease [1]. Ocular hyper-
tension has been reported in subjects without glaucoma
[2–5] and is more accentuated in patients with glaucoma
[6, 7]. Reports of intraocular pressure (IOP) rise during
dialysis in neovascular glaucoma are extremely limited [8].
It is generally accepted that dialysis may lower plasma
osmolality at a faster rate than changes in ocular osmolal-
ity. This osmotic difference causes water to migrate from
the plasma into the aqueous humor, increasing intraocular
pressure [9]. This theory has not however been clearly
demonstrated and some studies have indicated that IOP
increase is minimal or non existent, probably due to im-
provement in dialysis techniques. [10] Certain authors
have described IOP increase in patients with narrow
angles [11, 12]. Here we report a neovascular glaucoma
patient who experienced a substantial increase in IOP
associated with severe eye pain and blurred vision during
sessions of dialysis. The patient had been refractory to sev-
eral antiglaucoma drugs and improved after intravenous
administration of 20 % hyperosmotic glucose solution
with dialysis and pan-retinal photocoagulation. To our
knowledge this is the first report in which intravenous glu-
cose administration and reduction of neovascularization
by argon laser pan-retinal photocoagulation successfully
managed neovoscalar glaucoma.
Case presentation
The patient was a 48 year old male with end-stage renal
disease secondary to single pelvic Kidney, hypertension
and hypertriglyceridemia. Medical history included renal
failure in 2007 after kidney transplant, regular hemodialysis
in 1989 and home dialysis five times a week since 2014.
On 10 0ctober 2014, he was referred to our glaucoma unit
because of severe ocular pain and blurred vision during a
session of dialysis. The blurred vision resolved spontan-
eously within 2 h of onset. Nine years prior to this presen-
tation he had undergone cataract removal in both eyes
with intraocular lens implant in the right eye (RE) and
aphakia in the left eye (LE). He was first diagnosed with
neovascular glaucoma in 2013. Combined topical ß-
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blocker and carbonic anhydrase inhibitor (Cosopt®) and
prostaglandin analogue (Travatan®) were prescribed for
both eyes when intraocular pressure reached 38 and
34 mmHg in the right and left eyes, respectively. On pres-
entation, ophthalmological examination showed 2/20 best
correct visual acuity (BCVA) in the right and blindness in
the left eye. Anterior segment examination showed iris
rubeosis in both eyes (Fig. 1a): gonioscopy revealed neovas-
cularization spreading completely over the iridocorneal
angle with peripheral anterior synechiae at trabecular level
on the nasal and temporal sides, and OCT showed
evidence of “false angle” (Fig. 1b). Intraocular pressure
measurements were 22 mmHg RE and 21 mmHg LE.
When alpha2-agonist (Alphagan®) and pilocarpine hydro-
chloride 2 % eye drops were applied to both eyes, intraocu-
lar pressure decreased to 16 mmHg RE and 15 mmHg LE,
but blurred vision recurred in the right eye during dialysis.
The 30-2 Humphrey visual field test showed a large arcu-
ate scotoma in the upper and lower hemifields. Perimetric
defect type and stage were graded as mixed 2 by the
Brusini Glaucoma Staging System 2 [13]. In the left eye it
was impossible to perform visual field examination because
of poor visual acuity. Fundoscopic examination revealed
ischemic retinopathy with pre-retinal new vessels in the
optic disk area of both eyes (Fig. 2). An epiretinal mem-
brane covered the macular area of the right eye and ische-
mic peripheral retinal areas were observed. Seven years
earlier the patient suffered occlusion of the central retinal
vein in the left eye, followed in January 2014 by ischaemic
optic neuropathy. We began argon laser treatment of
ischemic peripheral retinal areas.
Intraocular pressure was measured five times during
hemodialysis for a 1-week period: at the beginning of
dialysis, at hourly intervals during dialysis, at the end,
and 1 and 2 h after the end of dialysis. Average intraocu-
lar pressure in the right eye at the beginning, after 2 h of
dialysis, at the end and 2 h later was 15, 30, 27 and
22 mmHg, respectively. Thus intraocular pressure in the
Fig. 1 Biomicroscopic (a) and OCT (b) images of anterior chamber showing angle closure due to neovascularization of the angle
Frezzotti et al. BMC Ophthalmology  (2016) 16:23 Page 2 of 5
right eye increased by 15 mmHg (100 %) during
hemodialysis. In the left eye it remained normal. Topical
instillation of eye drops did not prevent IOP increase in
the right eye. Hemodialysis was performed routinely five
times a week for 2 h and 40 min using central venous
catheter for chronic pyelonephritis using NxStage
System One (NSO) artificial kidney. After failure of eye
treatment, we administered intravenous glucose (20 %
glucose at 100 mL/h) during dialysis to prevent IOP rise.
We perform argon laser treatment between 60 and
30 days before dialysis. Eye pain and blurred vision re-
solved. We repeated IOP measurement during dialysis as
above and recorded mean values of 15, 16 and 18 mmHg
at the beginning, 2 h later and at the end of dialysis,
respectively. Differences between IOP before and after
i.v. glucose and panretinal photocoagulation treatments
are shown in Fig. 3. In the last ophthalmological evalu-
ation on 17 February 2015, BCVA was 2/20 in RE, anter-
ior segment examination showed reduction of iris
rubeosis in RE, IOP was 8 mmHg RE and 9 mmHg LE
and fundoscopic examination revealed successful argon
laser treatment of ischaemic peripheral retinal areas in
both eyes. The optic disk appear unchanged and the vis-
ual field stable after the two treatments. Alpha2-agonist
(Alphagan®) and pilocarpine hydrochloride 2 % eye drops
were discontinued. IOP was 13 mmHg RE and 12 mmHg
LE. No pain or blurred vision occurred again.
Discussion
Intraocular pressure may increase during hemodialysis,
as reported in many patients with and without glau-
coma. Many mechanisms have been invoked to explain
this phenomenon [1–12], the most frequent being that
IOP increases due to a rapid fall in plasma osmolality
that stimulates increased formation of aqueous humor
[2, 3, 9, 13]. This relationship between plasma osmolality
and IOP during hemodialysis has been studied since the
report of Sitprija et al. [14, 15]. Some authors have
suggested that decreased aqueous outflow might be the
mechanism of intradialytic IOP increase, since most
patients who showed IOP elevation during dialysis also
had a narrow anterior chamber angle [16, 17]. Rever et
al. [18] reported that anterior chamber depth decreased
significantly during dialysis. In the present neovascular
glaucoma patient, we suggest that raised IOP resulted
from an imbalance between aqueous outflow, obstructed
by angle closure due to new blood vessels, and
Fig. 2 Appearance of ONH in right eye
Fig. 3 Differences between IOP before and after i.v. glucose and panretinal photocoagulation treatments
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production of aqueous humor. The rise in IOP during
dialysis sustains this explanation: the drainage system
was unable to compensate the increase in aqueous pro-
duction during dialysis. Argon laser retinal photocoagu-
lation is known to reduce angle neovascularization
induced by peripheral retinal ischemia in neovascular
glaucoma patients [19, 20].
Several therapeutic solutions have been recommended
to prevent a symptomatic increase in IOP during dialysis
sessions. Medical expedients include topical and sys-
temic carbonic anhydrase inhibitor, which is relatively
contraindicated in dialysis patients as it can precipitate
severe metabolic acidosis, which might be fatal to
patients with end-stage renal disease [11]. Seo et al. [21]
used an oral hypertonic solution with glycerol that
proved effective for IOP control and safer in glaucoma
patients. Other therapeutic approaches were described
by Jaeger et al. who administered intravenous mannitol,
which reduced IOP but predisposed patients to various
side effects [17]. Other solutions include medical therapy
with topical Beta blockers [5], argon laser trabeculo-
plasty for exfoliative glaucoma [6], Ahmed valve implant
for neovascular glaucoma [8] and trabeculectomy for
diabetic retinopathy [22]. In our case, elevated IOP levels
during hemodialysis were refractory to topical treat-
ments and the patient’s young age and neovascular glau-
coma are both well-known risk factors for bleb fibrosis
and surgical failure [23, 24].
Intravenous glucose administration was recently
proposed to manage IOP increase during dialysis [25].
The authors showed that administration of 20 %
glucose solution (100 mL/h) at each dialysis session
prevented increased production of aqueous humor due
to relative serum hypo-osmolality. After this change of
treatment IOP remained in the normal range. One
limitation of high glucose administration could be the
overall increase in serum glucose in diabetic patients.
The most important side effect to be examined, in
patients with chronic kidney failure, is that chronic use
of hyperosmotic solutions does not reduce the effect-
iveness of hemodialysis. Effectiveness of hemodialysis
is calculated by artificial kidney’s software and it
depends on three parameters: BUN values before and
after hemodialysis sessions; body weight; time of
hemodialysis sessions. In our experience effectiveness
of hemodialysis has not changes until now and in
literature there aren’t studies on chronic use of
hyperosmotic solutions in these type of patients.
Another important side effect to be examined is the
possible establishment of hyperglycemia but also in
this case literature has not provided us more informa-
tion due to poor series but our patient has not had
alterations on glycemia values or on glucose intoler-
ance and performs bi-weekly all tests blood needed.
Before attempting surgery we decided to administer
intravenous glucose and to perform argon laser
treatment of ischemic peripheral retinal areas to reduce
neovascularization of the occluded angle. The synergy of
the two treatments, one aimed at reducing the produc-
tion of aqueous humor and the other at improving its
outflow, proved effective in controlling IOP during the
dialysis session and was safe for our neovascular
glaucoma patient with end-stage renal disease.
Conclusions
Our case of recurrent painful IOP spikes during dialysis
in a patient with neovascular glaucoma unresponsive to
conventional medical treatment is the first report in
which intravenous glucose administration and reduction
of neovascularization by argon laser pan-retinal photo-
coagulation successfully managed IOP increase during
dialysis. Further clinical studies are required to confirm
our results.
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